Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ahzantive (aflibercept-mrbb) / Amneal, Formycon, Coherus Biosci, Klinge Pharma
MAGELLAN-AMD, NCT04522167 / 2019-003923-39: Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration	Completed	3	434	Europe, Japan, RoW	FYB203 (Proposed aflibercept biosimilar), Eylea® (Aflibercept)	Bioeq GmbH	Neovascular Age-related Macular Degeneration	06/22	05/23